|
Market Cap (3-Jul) $146,035,872 (477th) |
Close (30-Jun) $0.99 |
Volume (30-Jun) 1,077,429 |
Shortsold (19-Jun) 1,473,254 (0.38%) (338th) |
|
52w High $0.66 |
52w Low $0.165 |
P/E - |
EPS -0.05 |
PAR released this announcement to the ASX on 18 February 2021, 10:49. The announcement is not marked as price sensitive, and is 6 page(s) in length and 260.72kb in size.
You can view all announcements from PAR and see how they appear on a price chart on the announcements page.
At the date of this announcement, PAR was 4.090% short sold according to ASIC data. It was ranked the 38th most shorted stock on the ASX. It remains ranked 338th as of the latest reported data (19 June 2025).
| Other Recent Announcements from PAR | |
|---|---|
| Notification of cessation of securities - PAR | 29 June 2023, 16:43 |
| Primary and Secondary endpoints met in MPS I Trial | 6 June 2023, 12:28 |
| iPPS shows 3-year equivalent durability in OA Canine Study | 1 June 2023, 8:21 |
| Ethics Approval Received for Synovial Fluid Biomarker Study | 18 February 2021, 10:49 |
| Paradigm Welcomes Helen Fisher as Non-Executive Director | 11 February 2021, 8:55 |
| Consistent pain reduction and improvement in function data | 3 February 2021, 8:18 |
| Statement pursuant to Listing Rule 4.7C.3 | 1 February 2021, 16:57 |
You must be logged in to post a reply.
Paradigm Biopharmaceuticals 